Adverse events (according to CTCAE v.5.0)
| . | Neutropenia . | Febrile neutropenia . | Thrombocytopenia . | Anemia . | Fever (after Ara-C infusion) . | Rash maculo-papular (after Ara-C infusion) . | Rash maculo-papular (vemurafenib-associated) . | Electrocardiogram QT corrected interval prolonged . | Headache . | Nausea . | Vomiting . | Other complications∗ . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 0 | 0 | 0 | 0 | 9 (47.4%) | 5 (26.3%) | 7 (36.8%) | 2 (10.5%) | 0 | 2 (10.5%) | 4 (21%) | 3 (15.8%) |
| Grade 2 | 0 | 0 | 0 | 0 | 3 (15.8%) | 2 (10.5%) | 0 | 0 | 3 (15.8%) | 4 (21%) | 1 (5.3%) | 3 (1.8%) |
| Grade 3 | 0 | 12 (63.2%) | 0 | 19 (100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5.3%) |
| Grade 4 | 19 (100%) | 0 | 19 (100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5.3%) |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| . | Neutropenia . | Febrile neutropenia . | Thrombocytopenia . | Anemia . | Fever (after Ara-C infusion) . | Rash maculo-papular (after Ara-C infusion) . | Rash maculo-papular (vemurafenib-associated) . | Electrocardiogram QT corrected interval prolonged . | Headache . | Nausea . | Vomiting . | Other complications∗ . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 0 | 0 | 0 | 0 | 9 (47.4%) | 5 (26.3%) | 7 (36.8%) | 2 (10.5%) | 0 | 2 (10.5%) | 4 (21%) | 3 (15.8%) |
| Grade 2 | 0 | 0 | 0 | 0 | 3 (15.8%) | 2 (10.5%) | 0 | 0 | 3 (15.8%) | 4 (21%) | 1 (5.3%) | 3 (1.8%) |
| Grade 3 | 0 | 12 (63.2%) | 0 | 19 (100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5.3%) |
| Grade 4 | 19 (100%) | 0 | 19 (100%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5.3%) |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTCAE,.
Infectious complications included: Herpes zoster infection, external otitis, earlobe abscess, BCGitis with lymphadenopathy, and meibomian cyst; grade 4 noninfectious complication is a secondary myelodysplastic syndrome.